A Phase 2 interventional study of ticagrelor and clopidogrel in Stable Coronary Artery Disease, sponsored by AstraZeneca. Completed at 14 sites in 2 countries. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-07-08.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing ticagrelor in Coronary Artery Disease — 5 open to participants now, 5 under way, 2 of them phase 3. Ticagrelor · Coronary Artery Disease.
Among the 78 studies testing ticagrelor in Coronary Artery Disease, this one is the 24th largest by enrollment, is the only one that started in 2010, is one of 7 in phase 2, and was the 5th registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →5 of the 78 studies testing ticagrelor in Coronary Artery Disease are open now, in 5 countries. Recruiting first, the newest first:
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
Shiraz University of Medical Sciences · Sites in Iran, Islamic Republic of
Ages 20–80
University of Florida · Sites in United States
Ages 18+
St. Antonius Hospital · Sites in Netherlands
Ages 18+
Campus Bio-Medico University · Sites in Italy
Ages 18+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 18 · Phase 4 46
First in 2006; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 146 is above the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.
Median enrollment 80 across the 78 interventional studies. Of the 59 that completed or were terminated, 26 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 78 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
25 studies in Coronary Artery Disease by AstraZeneca: 1 open now, 1 under way, none of them phase 3. Of 24 finished, 11 (46%) have results posted.
Among the 25 studies in Coronary Artery Disease by AstraZeneca, this one is the 8th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2010, is one of 5 in phase 2, and was the 9th registered.
AstraZeneca’s Coronary Artery Disease studies by the year they started, since 2001.
1 of the studies testing ticagrelor in Coronary Artery Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06228456University of FloridaEffects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 78 studies testing ticagrelor in Coronary Artery Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 25 in Coronary Artery Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ticagrelor
Drug: ticagrelor
Drug: clopidogrel
Drug oral treatment
Drug oral treatment
Inhibition of Platelet Aggregation(IPA) Final Extent at 2 Hours Post Dose on Week 4 in Japanese Patients
Final extent IPA from pre-dose baseline was calculated using the following formula for Adenosine Diphosphate (ADP)-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) Platelet Aggregation (PA) was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.
Time frame: Week 4
IPA Final Extent at 4 Hours Post Dose on Week 4 in Japanese Patients
Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.
Time frame: Week 4
IPA Final Extent at 8 Hours Post Dose on Week 4 in Japanese Patients
Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.
Time frame: Week 4
IPA Final Extent at 12 Hours Post Dose on Week 4 in Japanese Patients
Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.
Time frame: Week 4
IPA Final Extent at 24 Hours Post Dose on Week 4 in Japanese Patients
Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.
Time frame: Week 4
AZD6140 (Cmax) at Week 4
Maximum plasma AZD6140 concentration
Time frame: Week 4
AZD6140 (AUC0-tau) at Week 4
Area under the plasma concentration curve of AZD6140 from time zero to dosing interval
Time frame: Week 4
AZD6140 (Tmax) at Week 4
Time to reach peak or maximum concentration of AZD6140 following AZD6140 administration
Time frame: Week 4
AR-C124910XX (Cmax) at Week 4
Maximum plasma concentration of AZD6140 drug metabolite AR-C124910XX
Time frame: Week 4
AR-C124910XX (AUC0-tau) at Week 4
Area under the plasma concentration curve of AZD6140 drug metabolite AR-C124910XX from time zero to dosing interval
Time frame: Week 4
AR-C124910XX (Tmax) at Week 4
Time to reach peak or maximum concentration of AZD6140 drug metabolite AR-C124910XX following AZD6140 administration
Time frame: Week 4
In total, 146 patients were enrolled at 15 sites from 2 countries (Japan and Philippines). The study period was from April 2010 to March 2011. In total, 139 subjects were randomised and received the investigational product. Most subjects completed the study but 2 Japanese patients discontinued due to an AE during the 4 weeks treatment period.
| Milestone | AZD6140 45 mg bd | AZD6140 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|---|
| Started | 50 | 43 | 46 |
| Completed | 49 | 43 | 45 |
| Not completed | 1 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 1 |
Final extent IPA from pre-dose baseline was calculated using the following formula for Adenosine Diphosphate (ADP)-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) Platelet Aggregation (PA) was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.
| percentage inhibition | AZD6140 45 mg bd | AZD6140 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|---|
| Inhibition of Platelet Aggregation(IPA) Final Extent at 2 Hours Post Dose on Week 4 in Japanese Patients | 64.5 ± 14.8 | 73.0 ± 14.2 | 38.9 ± 20.7 |
Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.
| percentage inhibition | AZD6140 45 mg bd | AZD6140 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|---|
| IPA Final Extent at 4 Hours Post Dose on Week 4 in Japanese Patients | 67.3 ± 15.6 | 73.2 ± 15.1 | 43.7 ± 20.6 |
Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.
| percentage inhibition | AZD6140 45 mg bd | AZD6140 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|---|
| IPA Final Extent at 8 Hours Post Dose on Week 4 in Japanese Patients | 62.7 ± 17.7 | 68.6 ± 16.0 | 42.5 ± 20.2 |
Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.
| percentage inhibition | Arm 1 - AZD6140 45 mg bd | AZD6140 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|---|
| IPA Final Extent at 12 Hours Post Dose on Week 4 in Japanese Patients | 56.9 ± 20.9 | 66.8 ± 20.1 | 41.8 ± 21.7 |
Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.
| percentage inhibition | AZD6140 45 mg bd | AZD6140 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|---|
| IPA Final Extent at 24 Hours Post Dose on Week 4 in Japanese Patients | 46.2 ± 23.3 | 59.1 ± 20.3 | 38.0 ± 20.5 |
Maximum plasma AZD6140 concentration
| ng/mL | AZD6140 45 mg bd in Japanese Patients | AZD6140 45 mg bd in Non-Japanese Patients | AZD6140 90 mg bd in Japanese Patients | AZD6140 90 mg bd in Non-Japanese Patients |
|---|---|---|---|---|
| AZD6140 (Cmax) at Week 4 | 422 ± 230 | 341 ± 370 | 931 ± 442 | 1380 ± 343 |
Area under the plasma concentration curve of AZD6140 from time zero to dosing interval
| ng.h/mL | AZD6140 45 mg bd in Japanese Patients | AZD6140 45 mg bd in Non-Japanese Patients | AZD6140 90 mg bd in Japanese Patients | AZD6140 90 mg bd in Non-Japanese Patients |
|---|---|---|---|---|
| AZD6140 (AUC0-tau) at Week 4 | 3050 ± 1940 | 2930 ± 3740 | 6080 ± 2600 | 10900 ± 2790 |
Time to reach peak or maximum concentration of AZD6140 following AZD6140 administration
| hour | AZD6140 45 mg bd in Japanese Patients | AZD6140 45 mg bd in Non-Japanese Patients | AZD6140 90 mg bd in Japanese Patients | AZD6140 90 mg bd in Non-Japanese Patients |
|---|---|---|---|---|
| AZD6140 (Tmax) at Week 4 | 2.0 (1.9 to 4.0) | 4.0 (2.0 to 4.0) | 2.0 (1.9 to 4.1) | 4.0 (2.0 to 4.1) |
Maximum plasma concentration of AZD6140 drug metabolite AR-C124910XX
| ng/mL | AZD6140 45 mg bd in Japanese Patients | AZD6140 45mg bd in Non-Jpanese Patients | AZD6140 90 mg bd in Japanese Patients | AZD6140 90 mg bd in Non-Jpanese Patients |
|---|---|---|---|---|
| AR-C124910XX (Cmax) at Week 4 | 135 ± 53.3 | 101 ± 72.4 | 326 ± 139 | 381 ± 192 |
Area under the plasma concentration curve of AZD6140 drug metabolite AR-C124910XX from time zero to dosing interval
| ng.h/mL | AZD6140 45 mg bd in Japanese Patients | AZD6140 45 mg bd in Non-Japanese Patients | AZD6140 90 mg bd in Japanese Patients | AZD6140 90 mg bd in Non-Japanese Patients |
|---|---|---|---|---|
| AR-C124910XX (AUC0-tau) at Week 4 | 1180 ± 490 | 954 ± 741 | 2720 ± 915 | 3380 ± 1580 |
Time to reach peak or maximum concentration of AZD6140 drug metabolite AR-C124910XX following AZD6140 administration
| hour | AZD6140 45 mg bd in Japanese Patients | AZD6140 45 mg bd in Non-Japanese Patients | AZD6140 90 mg bd in Japanese Patients | AZD6140 90 mg bd in Non-Japanese Patients |
|---|---|---|---|---|
| AR-C124910XX (Tmax) at Week 4 | 4.0 (1.9 to 11.9) | 4.0 (2.0 to 8.0) | 2.1 (1.9 to 8.0) | 2.0 (2.0 to 4.0) |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD6140 45 mg bd | — | 2/50 (4%) | 13/50 (26%) |
| AZD6140 90 mg bd | — | 1/43 (2.3%) | 23/43 (53.5%) |
| Clopidogrel 75 mg od | — | 0/46 (0%) | 9/46 (19.6%) |
| Event | AZD6140 45 mg bd | AZD6140 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|---|
| LIP AND/OR ORAL CAVITYCANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/50 | 1/43 | 0/46 |
| GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 1/50 | 0/43 | 0/46 |
| PNEUMONIARespiratory, thoracic and mediastinal disorders | 1/50 | 0/43 | 0/46 |
| Event | AZD6140 45 mg bd | AZD6140 90 mg bd | Clopidogrel 75 mg od |
|---|---|---|---|
| Haemorrhage subcutaneousSkin and subcutaneous tissue disorders | 9/50 | 9/43 | 3/46 |
| NasopharyngitisInfections and infestations | 1/50 | 7/43 | 3/46 |
| Abdominal discomfortGastrointestinal disorders | 2/50 | 2/43 | 2/46 |
| ConstipationGastrointestinal disorders | 0/50 | 2/43 | 0/46 |
| Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders | 0/50 | 2/43 | 0/46 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/50 | 2/43 | 0/46 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/50 | 1/43 | 2/46 |
| HeadacheNervous system disorders | 2/50 | 1/43 | 0/46 |
| Age, Continuous(Years) | AZD6140 45 mg bd | AZD6140 90 mg bd | Clopidogrel 75 mg od | Total |
|---|---|---|---|---|
| Mean | 63 ± 11 | 64 ± 9 | 64 ± 10 | 63 ± 10 |
| Sex: Female, Male(Participants) | AZD6140 45 mg bd | AZD6140 90 mg bd | Clopidogrel 75 mg od | Total |
|---|---|---|---|---|
| Female | 4 | 3 | 8 | 15 |
| Male | 46 | 40 | 38 | 124 |
| Race/Ethnicity, Customized(Participants) | AZD6140 45 mg bd | AZD6140 90 mg bd | Clopidogrel 75 mg od | Total |
|---|---|---|---|---|
| Japanese | 42 | 35 | 40 | 117 |
| Non-Japanese | 8 | 8 | 6 | 22 |
The record gives a start of Apr 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 1 year 1 month after primary completion. A results delay was requested in Feb 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor